16 September 2026 editorial review · Item
GAD-alum antigen-specific immunotherapy (Diamyd): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: DIAGNODE-3 failure/discontinuation retained against sponsor primary updates; historical genotype-subgroup benefit did not establish replicated efficacy. No new programme revival located.
- Registry NCT03345004: COMPLETED; updated 2023-01-09; enrollment 109 (ACTUAL); primary completion 2020-07-13 (ACTUAL); results posted.
- Registry NCT05018585: TERMINATED; updated 2026-08-26; enrollment 321 (ACTUAL); primary completion 2026-06-24 (ACTUAL); results not posted in retrieved record.
- Primary publication/regulatory sources checked or consulted: jama.2013.6285; NEJMoa0804328; dc21-0318; s00125-020-05227-z; dgac343.
- Programme/sponsor/conference source boundary: Diamyd Medical reports negative interim results of Phase 3 DIAGNODE-3 trial (manufacturer); Diamyd Medical discontinues DIAGNODE-3 following evaluation confirming futility; initiates strategic review (manufacturer); Diamyd Medical provides an update on strategic review and financial position (manufacturer).